Trial Profile
PMOS: Kaletra Tolerability
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms PMOS
- Sponsors Abbott Laboratories; AbbVie
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 May 2015 Planned number of patients changed from 3000 to 3200, according to ClinicalTrials.gov record.
- 21 May 2015 Planned End Date changed from 1 Jan 2018 to 1 Jan 2016, according to ClinicalTrials.gov record.